Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.
about
A comparison of different antibiotic regimens for the treatment of infective endocarditisTeicoplanin versus vancomycin for proven or suspected infectionEfficacy of temafloxacin in experimental Streptococcus adjacens endocarditis and autoradiographic diffusion pattern of [14C]temafloxacin in cardiac vegetations.Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureusBactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.Right-sided endocarditis caused by Staphylococcus aureus in drug abusers.Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.Pharmacokinetic and pharmacodynamic requirements for antibiotic therapy of experimental endocarditisBeta-lactams versus glycopeptides in treatment of subcutaneous abscesses infected with Staphylococcus aureus.Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium.Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions.Teicoplanin in perspective. A critical comparison with vancomycin.Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis.Is therapeutic drug monitoring of teicoplanin useful?Therapeutic drug concentrations of teicoplanin in clinical settings.Cochrane meta-analysis: teicoplanin versus vancomycin for proven or suspected infection.Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic responseClinical evaluation of teicoplanin fluorescence polarization immunoassay.Teicoplanin: 10 years of clinical experience.Anti-infective treatment in intensive care: the role of glycopeptides.Use of teicoplanin in community medicine.Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study designShort-course therapy for right-side endocarditis due to Staphylococcus aureus in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin.Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy.Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections
P2860
Q24185887-A55852D2-6F1B-469E-B4DA-7D7413B378A8Q24234764-697C4765-1759-467C-BE49-E8A794F85B94Q30833424-EC32B3F7-73B3-4512-B367-670782E6B038Q33756241-0FF7BB75-C7B0-4B74-A241-CB53391986C7Q33758399-5557D2F9-0446-4B71-B505-7DAC1D2DB7AEQ33758447-5AD0E169-A9CA-48FA-8C83-E3E3BD8B4C9FQ35014464-E8B5B9F0-DAF0-4B3F-98EF-CDCDF8692B9AQ35111909-244CAFBB-D480-489B-B46A-0417C940FCB2Q35138989-8D4C6540-6217-4222-A6C7-1115A8BC48F0Q35534742-9CFA9A92-2D4C-4AB6-8233-FF95B633CCB1Q35820407-158F339A-719C-4802-BB58-4581F498A8CCQ36409465-5B5A7BE0-CDE9-4EDC-B9F9-DD41DE76B9C7Q36754480-11AE6FAF-2B66-4E7F-AB7C-6D3D17331BE1Q36758570-418B7F1D-B7BB-447A-8565-7B5EBE00D246Q37113420-D6669FA9-FD89-4CEC-A1D4-44F7F9F1999FQ37392738-CCDFC1D4-A905-4C20-B948-2DA20F69EAC6Q37673485-14B78400-36E6-4264-88E6-55AF2D1C7A30Q37673498-73669C56-5A01-49B9-8E28-AF6F160D48E6Q38694776-7C22200B-8965-494B-A5CC-8B820CA8C4F3Q39881225-C1F03C94-FA36-4676-A3AE-4A8B681C379DQ40087066-CAFE47F6-B96A-4B21-A075-511EAF1CCF9EQ40495612-F72B1616-AFCD-43B5-96F3-59CEE4B058A5Q40495770-4609AF59-75DE-42AD-B468-A9F7C57A1B58Q40584161-B97CE127-194C-447E-BBDE-BFEAD0362C16Q42544277-80DAD49E-073F-4F4E-A547-C12F6CB28989Q43453462-14EF03F8-69EE-463E-AA31-1DEAB0C63AA3Q47634145-09020DE4-BCC0-4641-92EF-F9A7B1E84C87Q53879693-D07DAF67-41DC-4145-BF81-8DAB2C0E8F7BQ57149999-E3A9C02E-68D7-4734-83F6-CC5EB15A8A74
P2860
Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
1991年论文
@zh
1991年论文
@zh-cn
name
Failure of treatment with teic ...... Diseases Consortium of Oregon.
@en
type
label
Failure of treatment with teic ...... Diseases Consortium of Oregon.
@en
prefLabel
Failure of treatment with teic ...... Diseases Consortium of Oregon.
@en
P2093
P2860
P356
P1476
Failure of treatment with teic ...... Diseases Consortium of Oregon.
@en
P2093
P2860
P356
10.1128/AAC.35.1.79
P407
P577
1991-01-01T00:00:00Z